GS-6615

DRUG4 trials

Sponsors

Gilead Sciences

Conditions

Ischemic Heart DiseaseLong QT Syndrome

Phase 1

A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects

CompletedNCT01847391

Gilead SciencesIschemic Heart Disease

Start: 2013-05-31End: 2013-11-30Updated: 2013-11-13

Study of the Effect of GS-6615 in Subjects With LQT-3

CompletedNCT01849003

Gilead SciencesLong QT Syndrome

Start: 2013-05-31End: 2014-11-30Updated: 2014-11-17

Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults

CompletedNCT02365532

Gilead SciencesLong QT Syndrome

Start: 2015-02-28End: 2015-05-31Updated: 2015-05-20

Phase 2

GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease

WithdrawnNCT02377336

Gilead SciencesIschemic Heart Disease

Start: 2015-05-31End: 2016-08-31Updated: 2015-06-08